Biopharma deals roundup: Mentari's $200M migraine raise, Royalty Pharma's $425M ATTR-CM royalty buy, Dyne's $375M stock offering and Tikva Allocell's $8M Series A.
July 22, 2026 10:17 AM EDT
Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal
Another $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine…
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat…
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired…
Vedana Therapeutics exits stealth with $46M Series A to develop anti-PACAP and bispecific PACAP/CGRP treatments for migraine…
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a…
Mirador Therapeutics licenses Kira Pharmaceuticals' KP-301 for $12M to treat ANCA-associated vasculitis, competing with Amgen's…
